Replies to post #164655 on Cytodyn Inc (CYDY)

[DonDonDonDon]

And according to dr Patterson only about 20-25% patients with covid showing higher GM-CSF.

And the patients who have elevated GM-CSF are the exact patients who go on to be severe and die. Patients who don't have elevated GM-CSF will recover on their own.

Obviously, lenzilumab being an GM-CSF inhibitor puts it in a nice position to be a game changing Covid treatment. But any treatment could use GM-CSF detection in their trial. For instance, leronlimab could redo their mild-to-moderate trial while only giving it those with elevated GM-CSF. Their efficacy would be much better. Maybe they could even show a mortality benefit by targeting the patients who are the ones at risk of becoming severe and dying.

https://www.bbc.com/news/health-56352128